ArticleFrontiers in immunology2025
Establishment of an anaplastic stratification signature for gastric cancer based on diverse regulated cell-death.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Met@MPDA rejuvenates BMSC energy metabolism to promote bone regeneration in semaglutide-treated obese periodontitis.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer is a common malignant tumor characterized by poor prognosis and limited therapeutic options. The combination of Regulated cell death inducers and enhancement of the immune therapeutic effect plays an important role in cancer treatment. Methods: We downloaded and analyzed data from gastric cancer samples, collected 14 Regulated cell death-related genes and constructed a Regulated Cell Death-Related Index (RCDRI) by various machine learning methods. Based on the RCDRI, gastric cancer patients were divided into high RCDRI and low RCDRI groups, and the clinical characteristics, immune cell infiltration, chemotherapy response and immunotherapy response of gastric cancer patients were analyzed based on the RCDRI. Results: The newly constructed RCDRI consisted of four Regulated cell death-related genes (CD36, SERPINE1, TRIML2, and GRP) and has been shown to be an effective predictive marker for the survival of gastric cancer patients and was trained with multiple external datasets. The high RCDRI group had a higher level of immune cell infiltration and better response to immunotherapy than the low RCDRI group. In addition, through pan-cancer analysis, we found that RCDRI can also be used for prognosis and immunotherapy prediction in a variety of cancers. Finally, Conclusions: The RCDRI identified in this study can accurately assess the prognosis and immunotherapy efficacy of gastric cancer patients, which lays a valuable foundation for future clinical treatment of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.